Skip to main content

01.12.2017 | Case report | Ausgabe 1/2017 Open Access

BMC Cancer 1/2017

Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromes

BMC Cancer > Ausgabe 1/2017
Ema Kantorová, Michal Bittšanský, Štefan Sivák, Eva Baranovičová, Petra Hnilicová, Vladimír Nosáľ, Daniel Čierny, Kamil Zeleňák, Wolfgang Brück, Egon Kurča
11methyl-methionine positron emission tomography
1H–proton MR spectroscopy
Antigen Presenting Cell
Central Nervous System
Cerebrospinal Fluid
Computer Tomography
Deoxyribonucleotid Acid
Expanded Disability Status Scale
Glial Fibrillary Acidic Protein
Glial Tumour
Hematoxylin and Eosin
Human Leukocyte Antigen
Isocitrate Dehydrogenase1
Immuno-modulatory Treatment
Immune Reconstitution Inflammatory Syndrome
John Cunningham virus
a nuclear protein that is associated with cellular proliferation
Magnetic Resonance Imaging
Multiple Sclerosis
a high molecular weight transmembrane protein expressed by oligodendrocytes in white matter of the CNS
Oligodendrocyte transcription factor
cellular tumour antigen
Polymerase Chain Reaction
Progressive Multifocal Leukoencephalopathy
Simian Virus 40
Tumefactive Demyelinating Lesion
Transforming Growth Factor-β
Visual Evoked Potentials


Multiple sclerosis (MS) is a disabling inflammatory demyelinating disease of the central nervous system (CNS). Early initiation of immunotherapy and its adjustment in view of ongoing inflammatory disease activity is desirable [ 1]. The main treatment goals aim at terminating inflammation and at reducing axonal damage [ 1]. Establishing MS diagnosis and decisions about the initial and ongoing treatments should not be made until other disorders that could better explain neurological symptoms and signs are excluded [ 1]. Although glial brain tumors (GT) have occasionally been reported in patients with MS, with only about 80 cases described in medical literature so far [ 25], this co-occurrence is uncommon since MS is caused by putative CNS autoimmune mechanisms whereas brain neoplasms may depended on a subclinical immunosuppressive state [ 6]. However, the last 15 years have seen increased use of immunomodulatory therapies (IMT) for relapsing MS, and considerable progress in the development of new, much stronger IMT for MS [ 7]. That rises questions about long-term safety of IMT as well as their risks and benefits [ 7]. Currently we know that several IMT make patients more susceptible to developing dangerous brain infection caused by John Cunningham virus (JCV) called progressive multifocal leukoencephalopathy (PML) [ 812]. However, MRI findings of tumefactive demyelinating lesions (TDL), PML and GT can overlap [ 1219]. The first appearance of atypical brain lesion in an MS patient should lead to more extensive investigation in order to exclude another disease [ 1519]. However, in some cases only biopsy is capable to reveal the cause of atypical MRI lesion [ 20, 21].
Here we describe the case of a malignant GT in a patient with early onset of MS. To the best of our knowledge, anaplastic astrocytoma misdiagnosed as PML has not yet been described. We discuss diagnostic tools that can help in differential diagnosis.

Case presentation

Here we report on a 27-year-old woman with the first neurological symptoms suggesting MS in 1999 at the age of 12. Her medical and psychosocial history was negative, but her family history was positive. Patient’s father is also treated for MS. The patient’s clinical timeline follows (Figs. 1, 2, 3, 4, 5, 6 and 7):
A 12-year-old girl with negative medical history presents with vestibular syndrome lasting three weeks
After having experienced several relapses with various symptoms (paresthesias of her left and right upper limbs, paresthesias of her distal limbs, weakness of upper limbs), she fulfilled McDonald criteria for definite relapsing-remitting MS due to demyelinating lesions in MRI (Fig. 1a, b, c), positive oligoclonal bands type 2 in cerebrospinal fluid (CSF) and positive visual evoked potentials (VEP).
2006 October
Several rounds of intravenous boluses of methylprednisolon were effective and the patient improved. When she started treatment by interferon beta Ia (Rebif® Merck-Serono), her Expanded Disability Status Scale (EDSS) was 2.0.
The treatment was interrupted due to her pregnancy in February 2008. In January 2009 she gave birth. During the early postpartum period the patient’s neurological status was unstable.
2009 January to April
The patient suffered three relapses (sensitive symptoms, left-sided hemiparesis, paraparesis of distal limbs) and her EDSS increased to 4.0 although she obtained several rounds of intravenous methylprednisolon.
2009 May
She resumed interferon beta Ia (Rebif® Merck-Serono) and reached remission.
2011 March to May
Her disease progressed again, her EDSS increased to 4.5 and follow-up MRI reflected clinical activity (Fig. 2a, b). Central quadruparesis was more pronounced in her left limbs and spinal ataxia varied over time between a need of assistance when walking longer distances and mild deficit. She responded well to intravenous methylprednisolon rounds.
2012 August
To stop the disease progression, she was indicated to natalizumab (Tysabri® Biogen Idec), receiving 12 infusions (august 2012 - september 2013).
2013 September
The follow-up brain 3.0 Tesla MRI showed enlargement of the lesion in the right frontal lobe, evaluated by radiologists as PML (Fig. 3a, b, c, d). We also noticed seroconversion of JCV antibodies, but JCV index was low (0.38) and CSF PCR of DNA revealed no copies of JCV (Focus diagnostics, CYPRESS, California, USA).
2013 December
Not meeting Slovak indication criteria, the patient ceased taking natalizumab. The patient started treatment with fingolimod (Gilenya® Novartis Pharmaceuticals UK). At that time she was quadruparetic, more prominent on the left side. She needed assistance due to wide-based gait and she had intermittent headaches (mild to moderate congestive-dull or pulsating headache located in bi-temporal areas, partially alleviated by analgesics) EDSS was 5.0.
2014 February
A follow-up 3.0 Tesla MRI of the brain showed enlargement of the prior frontal lobe lesion (Fig. 4a, b, c), misinterpreted as PML again. A new CSF examination showed normal proteinorhachia (0.22g/l) and cellularity (1lymphocyte), not increased lactate (1.91 mmol/l), positive oligoclonal bands type 2 (14 bands), and increased IgG index 1.44. The PCR test of DNA JCV was negative again (0 copies UNILABS, Denmark). We decided to continue with fingolimod.
2014 December
Over the following several months she developed new clinical symptoms: headache, sporadic epileptic seizures, disorientation. Immunomodulatory treatment was stopped. Repeated MRI was comparable with the MRI from February 2014, the atypical lesion in the right frontal lobe was in mild progression.
2015 May
1H-magnetic resonance spectroscopy ( 1H-MRS) detected decreased creatin to cholin ratio in several small areas of the frontal lobe, possibly suggesting tumorous mass (Fig. 5) Brain biopsy of the tumefactive lesion from the right frontal lobe.
Histopathological findings revealed presence of anaplastic astrocytoma (Fig. 6a, b, c, d, e)
2015 June
The patient needed anti-oedematous (dexamethason or methylprednisolon, boluses of manitol) and anti-epileptic therapy (valproic acid and levetiracetam) due to repeated secondary generalized epileptic seizures and intracranial hypertension syndrome.
2015 August
Before starting oncological treatment, 11methyl-methionine positron emission tomography ( 11C MET PET) showed cortical localization of the brain tumor (Fig. 7). Patient’s condition remained unstable due to frequent epileptic seizures. Three weeks later she suddenly died during status epilepticus (23/Aug/2015).

Discussion and conclusions

Our case shows that MS can have variable presentation therefore concurrence of MS with brain tumours may remain undetected for some time. One possible explanation is that an association of MS with overall risk of cancer has not been proved [ 22, 23]. One meta-analysis even identified a small but significant reductions of total cancer risk in patients with MS (odds ratio [OR] 0.92; 95% CI 0.87–0.97, p = 0.004) [ 24]. Another meta-analysis suggested lower overall co-occurrence of cancer in patients with MS [ 24]. On the other hand, a recent large systematic study evaluating risk and survival of brain tumours among patients with autoimmune disorders found higher standardised incidence of brain tumours in MS (OR 2.14; 95% CI 1.65–2,73) than in other autoimmunity disorders of the CNS [ 25]. The most frequent brain tumours were gliomas with OR 1.49; 95% CI 0.91–2.31. In this study, the risk of glioma-associated deaths in MS patients was relatively high (OR 2.3; 95% CI 1.47–3.61). In addition, the data on survival showed the same decrease for both benign and malignant types of tumours co-occurring with MS [ 25]. Curiously, MS was the only autoimmune disease for which the overall brain cancer and especially glioma-specific survival appeared to decrease in recent years [ 25]. One explanation could be that comorbidity weakens patient’s physical condition. Moreover in MS, glial tumours interfere with mortality burden due to reduced treatment options and lower capacity of the affected brain to resist tumour growth. Another explanation could be that brain tumours remain hidden in demyelinated brain tissue and therefore they are diagnosed later, in advanced stages, which was also our case.
At the beginning of our patient’s disease the pathological lesion was connected to the frontal pole of lateral ventricle stretching to the periphery dispersing into the white matter. It was T2- and FLAIR- hyperintense and its localisation near the ventricle favoured TDL over GT (Fig. 1b,c). MRI of the atypical lesion fulfilled the reported characteristics of TDL [ 1518]. However, MRI signs of TDL and GT can overlap easily [ 15, 17, 18]. Brain CT examination may be helpful in differentiation between the TDL and malignant GT [ 26] but we did not perform it in the early stage. Later, growth activity of the atypical lesion in the frontal lobe, good response to steroids, and absence of clinical signs suggesting tumour [ 1518] led to treatment escalation. The effect of natalizumab and fingolimod to the lesion growth was evident and its MRI characteristics evoked suspicion of PML [ 1113]. Although CSF examination of DNA JCV is a reliable test of PML, there were also reported cases of PML in JCV-PCR CSF negative patients in early PML as well as during Immune Reconstitution Inflammatory Syndrome (IRIS) [ 27].
In our patient, minimal mass effect and absence of post-contrast enhancement supported PML diagnosis [ 1113]. Double Inversion Recovery (DIR) (Fig. 4c) confirmed cortical involvement but did not add new information. Cortical lesions are typical for advanced forms of MS but they can be found in PML as well as GT [ 1113, 1720]. Diffusion Weighted Imaging (DWI) hyperintensities (Fig. 3d) favoured PML [ 1113]. 1H–MRS revealed decreased creatine to choline ratio in several areas of the lesion. We did not find changes of glutamate and glutamine peaks, as was reported by Yamashita [ 14]. 1H–MRS is able to identify brain tumours or demyelination [ 11, 2831] although several authors recommend caution when interpreting 1H–MRS measured concentrations of metabolites in isolation [ 11, 31]. As our lesion was not well defined its precise place was estimated. Its localisation and size was finally revealed by 11C MET PET. Increased uptake of 11C–MET, i.e. high proliferation index of 11C–MET indicating malignancy [ 32], was found in the right cortical frontal area. Slightly increased uptake of 11C–MET was also found in left frontal and occipital cortex.
Cortical clinical symptoms, including disorientation, confusion, epileptic seizures, behavioural changes and headaches appeared in our patient in terminal stages of GT progression. They can also be found in patients with PML [ 811]. Moreover, symptomatic seizures correlate with cortical demyelination in advanced forms of MS [ 33], and could be associated with TDL [ 15, 16].
Basic CSF examination in our patient showed normal proteinorhachia and cell count, but increased number of oligoclonal bands type 2 (14 bands) and IgG index 1.44. These findings suggest active demyelinating processes associated with MS [ 15, 34] or PML-IRIS [ 10, 11]. This reaction is unusual in GT, where increased lactate in CSF and hyperproteinorrhachia would be expected [ 6]. However, we did not prove it.
Retrospective analysis of the blood cellular immunity over the years showed chronic increase of CD4+ (50–66%) and mild deficit of CD8 (11–12% with higher CD4/8 index (4.5–5.0) at the beginning of her disease (2007–2009). During interferon beta I treatment, CD4+ (55%) and CD8 (10%) remained unchanged, while CD16 + CD56 Natural Killers (NK) (4%, 66 abs) fell, and CD19 rose (31%, 513 abs). Natalizumab chronically decreased CD8 subpopulations of T lymphocytes. Fingolimod reduced CD4+ but significantly increased % of NK (49%). Humoral immunity remained normal and unchanged during all that time. Deficit of NK cells in our patient could decreased resistance against brain tumour growth, as NK cells can play an important role in anti-tumour immunity [ 35]. Moreover, it is known that in MS, autoimmune conditions are mediated mostly by CD4+ T-cells with a proinflammatory Th1 and Th17 phenotype, causing inflammation and demyelinating lesions in the CNS [ 36]. The dominancy of glial tumours in MS leads to a hypothesis that chronic hyperactivation of glial cells via Th1/Th17 pathways could cause their neoplastic transformation in demyelinated lesions [ 34]. On the other hand, if MS-associated proinflammatory Type17 T-cells mediate potent antitumour immunity [ 34], suppression and sequestration of those cells could potentially cause its breakdown. We did not test our patient’s Th17 lymphocytes, the mechanism could only be hypothesised. During natalizumab and fingolimod treatment we found lymphocytes decreased in periphery but we are not able to describe changes in the brain of our patient. This selective deficiency could have been involved in inefficient antitumour immune surveillance and tumour progression [ 37, 38].
Treatment by IMT could potentially trigger a variety of immunologic abnormalities that are typical for patients with malignant brain tumours [ 38, 39]. IMT may targeted many factors such as impaired responsiveness of peripheral blood lymphocytes to mitogens [ 39], failure of the T cells mediating adaptive immune responses within the local tumour micro-environment [ 40], and induction of regulatory T cells [ 41]. Development of GT can potentially be influenced by immunosuppressive cytokines (such as IL-10, TGF-β, and prostaglandin E2), and by down modulation of co-stimulatory molecules by antigen presenting cells (APCs) resulting in loss of T cell effector function [ 41]. Long-term monitoring of these markers in patients treated by highly effective IMT could be beneficial.
In tumour vessels, aggressive endothelial proliferation [ 42, 43], increases CD34+, a marker of endothelial progenitor cells [ 42]. Although natalizumab treatment results in an increase in CD34+ progenitor cells in both the bone marrow and the blood [ 44], it is not clear whether it can enhance tumour angiogenesis in a brain tumour. Moreover, increased angiogenesis was also described in PML lesions [ 11].
Indeed, the CNS biopsy remains the most useful method for defining the histological type of an atypical brain lesion susceptive of tumour. In our patient, Vimentin’s over-expression in cancer correlates well with increased tumour growth, invasion and poor prognosis [ 45]. OLIG2 is highly expressed in all diffuse gliomas [ 46] and was found expressed in our patient’s anaplastic astrocytoma samples. Tumourous cells were Nogo positive, Nogo-A exerts a growth inhibitory function leading to restricted axonal regeneration [ 47]. In our case Ki-67 was ≤5% but >2%. Worsened survival has been associated with Ki-67 > 2% [ 48]. Mutation of IFH1 and positive p53 in our patient suggests secondary nature of the astrocytoma [ 49].
In our patient we did not prove the histopathological triad of PML (multifocal demyelination, hyperchromatic, enlarged oligodendroglial nuclei, and enlarged bizarre astrocytes with lobulated hyperchromatic nuclei) [ 11, 27], which would have been a rather convincing evidence of the disorder. In Table 1, we summarise the differential diagnoses of tumefactive demyelinated lesions, malignant glial tumours, PML and PML associated with IRIS. We hypothesise that IMT may have transformed the glial cells into malignant GT. However, in a descriptive study among 22,563 French MS patients, including patients receiving IMT, brain tumours were not detected in total of 253 patients (1.2%) with a history of cancer [ 45]. In the SENTINEL trial of natalizumab in combination with interferon beta-1a, the incidence rate of cancer in the combination group ( n = 589) was 1% compared to 2% in the interferon beta-1a alone group ( n = 582) [ 50]. In interim analysis of TOP study, including 4821 patients from 16 countries, the incidence of malignancies was 0.5%. There were 24 patients with 12 types of malignancies. Glioblastoma was detected in 1 patient, while breast cancer was the most common, affecting seven patients (all female) [ 51].
Table 1
Differential diagnoses of tumefactive demyelinated lesions, malignant glial tumours, progressive multifocal leukoencephalopathy and progressive multifocal leukoencephalopathy associated with immune reconstitution syndrome
malignant GT
Clinical sy
motor, cognitive (aphasia, apraxia, agnosia, Gerstman, coma) sensitive, cerebellar, brain stem. Visual field defects, Epileptic seizures
epileptic seizures, cognitive and memory deficit, motor, sensitive.
altered mental status (aphasia), motor, limb and gait ataxia, visual symptoms: homonymous hemianopia, cortical blindness, diplopia. Epileptic seizures. No optic nerve and spinal cord involvement.
altered mental status (aphasia), motor, limb and gait ataxia, visual symptoms: hemianopia, cortical blindness, diplopia. Epileptic seizures. No optic nerve and spinal cord involvement
[ 814], [ 52]
MRI T2w/
Unilateral or bilateral. Frontal, parietal. Periventricular, juxta cortical. 2 cm, large lesion with little mass effect and edema Variable rate of hyper-intensity. Central dilated vessel.
Irregular border. Supra-tentorial WM, partially GM involvement.
Unilateral. Supra-tentorial.
Hyper or hypo intense.
Irregular border. Central necrosis.
Intensive vascular edema and mass effect
Bilateral. Supra-Intra-tentorial. Cortex, deep gray matter. (Frontal, parietal, occipital. Subcortical location, U-fibers, cortex, basal ganglia). 3 cm.
Early new lesions. Hyper-intense. Ill-defined to WM, sharp to GM.
No mass effect. Punctuate perilesional lesions.
Bilateral, spreading. Cortex and subcortical WM. Edema
[ 1118], [ 16, 26, 54]
CT- hypo-intensity
Hypo-intense. CT-hypo-intensity
CT-hypo intensity
Hypo-intense with hyper- intense rim
[ 1118], [ 26, 54]
MRI Gd +
incomplete rim enhancement
complete rim enhancement
negative or variable, punctuate and rim like
positive or variable, punctate and rim like
[ 1118], [ 26, 54]
decreased PWI in lesions, increased DWI in active demyelination
increased PWI, increased DWI in central necrosis
DWI always hyper-intense, with peripheral rim.
+/− restricted DWI
[ 918, 26]
increased Cho, lipids, lactate, mildly decreased NAA and NAA/Cr (differ from malignant GT)
elevation of the β ,γ -Glx peaks
increased Cho and Cho/Cr, lipids, lactate, decreased NAA, lack of β ,γ -Glx elevation
A decrease of NAA/Cr ratio, NAA and Cr. An increase of Lac/Cr, Cho/Cr, Cho, lipids/Cr, mIns, Lac, Lip.
increased Cho, decreased NAA, the presence of Lac/lipids at 1.3 ppm, and the presence of mIns, Higher Cho/Cr, mIns/Cr, Lip1/Cr, and Lip2/Cr in PML-IRIS than PML .
Lower NAA/Cr than PML.
[ 11], [ 13, 14], [ 2831]
CSF native
normal or mild increased proteinorhachia and white blood count.
Positive oligoclonal bands, elevated IgG index
GFAP+ cells
mildly increased cellularity, normal proteinorhachia
mild to moderate increase of lymphocytes and protein levels
[ 10, 11], [ 14, 15]
negative, infrequently low positivity (less than 25)
negative? unknown
JCV-specific IgG, DNA copies, infrequently negative
JCV-specific IgG, DNA copies. Sometimes negative
[ 1218, 31]
Response to corticoids
very good
only partial
[ 2, 911], [ 15, 27]
Hyper-cellularity, myelin protein-laden macrophages, variable lymphocytic inflammation, reactive gliosis and relative axonal preservation.
moderate cellularity, bizarre cells with hyperchromatic nuclei, moderate pleomorphic, gemistocytes, perivascular lymphocytes, rare areas of necrosis, neo-vascularization
GFAP + cells: immature,
reactive, and neoplastic astrocytes and ependymal cells
swelling of oligodendrocyte and multi-lobular astrocytes, basophilic nuclei, eosinophilic inclusion bodies,
2/3 of number of T cells in PML-IRIS.
Positive DNA JCV staining in all types of cells. Active gene copies in high numbers of virally infected cells, as well as a low inflam- matory infiltrate.
Hyper-cellularity, CD8+ positive T cells dominate - their number the same as in active MS lesions, fewer CD4+ and CD20+ T cells in perivascular cuffs.
High plasma and B cells in PML-IRIS-lesions.
No or low number JCV-infected cells.
[ 2, 10], [ 15, 1720, 49], [ 4143, 4648],
[ 54, 55]
as typical MS
progressive worsening
progressive worsening
worsening, regression possible
[ 6, 1020, 49], [ 24, 25], [ 47, 48], [ 51]
Immunological markers in peripheral blood
upregulation of transcription factors of Th1 (pSTAT1 and T-bet) and Th17 (pSTAT3) in circulating CD4+, CD8 + T-cells and monocytes. CD4+ T-cells with a proinflammatory Th1 and Th17 phenotype,
lower T-bet, pSTAT1, and pSTAT3 in CD4+, CD8 + T-cells, and monocytes. Lower CD4 Th1 and Th17. Increased IL-10, TGF-β , PGE2, down modulation of co-stimulation molecules by APCs. Tumor angiogenesis, expression of CD34+ progenitor cells.
Deficit of NK cells
variable data: stable CD4+ and CD8+, non-significant decrease or increased T cells but unchanged CD4/CD8 ratio. Decrease expression of CD49d, CD29 (VLA-4), CD11a, CD62L, CXCR3 on T cells. Decreased expression of VLA4 on myeloid dendritic cells, decreased count of dendritic cells. Production of CD34+ cells, increase of memory B cells. Increased IL-10.
Increased IFN-γ, IL-12p70, IL-4, IL-10, IL-5, IL-13.
CD4+,T1 + PSTAT3+, CD8+, PSTAT1+,T-bet + .
Decreased CD4+, CD25+ FoxP3+
[ 3648, 56] [ 54]
TDL tumefactive demyelinating lesion, GT glial tumour, PML progressive multifocal leukoencephalopathy, PML-IRIS PML -immune reconstitution inflammatory syndrome, MRI T2w T2 weighted imagines of magnetic resonance imagine, MRI T1w T1 weighted imagines, DWI diffusion weighted imagines, PWI perfusion weighted imagines, GAD gadolinium enhancement, WM white matter, GM gray matter, CT computer tomography, 1H–MRS proton magnetic resonance spectroscopy, Cho cholin, NAA N-acetyl aspartate, Cr creatine, Lac lactate, mIns myoinositol, βγGlx βγ glutamate + glutamin, Lip lipids, NK natural killers, VLA4 alfa integrin 4, IL 4,10,12,13 interleukin 4,10,12,13, CD4 T helper lymphocytes, CD8 T suppressor lymphocytes, CD11 alfa component of various integrins, CD20 B-lymphocyte antigen, CD28 proteins expressed on T cells that provide co-stimulatory signals required for T cell activation and survival, CD34+ hematopoietic progenitor cell antigen, CD49 an integrin alpha subunit, CD62 a cell adhesion molecule found on lymphocytes, CD25+ FoxP3+ regulatory T cells, IgG imunoglobulin G, CXCR3 a chemokine receptor that is highly expressed on effector T cells and plays an important role in T cell trafficking and function, JCV John Cunningham virus, TGF-β transforming growth factor β,PGE2 = prostaglandin E2, GFAP glial fibrillar acidic protein, STAT 1,3 Signal transducer and activator of transcription 1,3, Th1 T1 lymphocytes, Th17 T17 lymphocytes, T-bet transcription factor, APC antigen presenting cells, CSF cerebrospinal fluid, DNA deoxyribonucleic acid
Our patient was the carrier of human leukocyte antigens (HLA)-DRB 1*15 and DRB 1*11 alleles, and heterozygote of single nucleotide polymorphism rs3135388, which is typical for multiple sclerosis [ 52]. Although expression of HLA antigens is important for the immune response against infectious agents and malignant cells, there is an information gap about the link between HLA antigens and brain glial tumours. However, one prospective study, focused on HLA typing of German Caucasian patients, found that HLA-DRB1*15 in combination with HLA-DRB1*11 was associated with higher (a 13.4-fold increased) risk of glioma than was found for other HLA alone or in other combination [ 53]. It might explain the occurrence of astrocytoma Grade III in our patient.
We suppose that the anaplastic astrocytoma in our patient, developed after the diagnosis of MS, could have arisen in demyelinative plaques with reactive gliosis and could have evolved from a low grade glioma to anaplastic astrocytoma over time. The role of the immunomodulatory treatment as well as other immunological factors in malignant transformation of the tumour can only be hypothesised. The association between gliomas and MS is uncommon but it must be kept in mind when an atypical tumefactive lesion develops in a patient with MS. In our case, it is the first time when malignant glioma was misdiagnosed as PML.


The authors wish to thank Ms. Hana Jesenska who assisted in the proofreading of the manuscript.


The work has been supported in the data analysis and writing of the study by the Project VEGA 1/0287/16 and Grant APVV 15/0107.

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

EKa: manuscript writing, analysis and interpretation of data; JM: patient follow-up examination; WB:histopathological analysis; MB, PH, EB, SŠ, EKu: literature search, analysis and interpretation of data; KZ: analysis and interpretation of radiological tests; DČ: genetic analysis; All authors read and approved the final manuscript.

Competing interests

On behalf of all authors, the corresponding author states that there is no conflict of interest. The authors alone are responsible for the content and writing of the paper.

Consent for publication

Written informed consent was obtained from the next of kin of the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the editor of this journal.

Ethics approval and consent to participate

Ethics committee of Jessenius Faculty of Medicine at Comenius University (Slovakia) approved the study under number EK 1678/2015.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Cancer 1/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.